If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-08. Numbers and descriptions here follow the published literature rather than marketing material.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
27 May – A study published in Light: Science & Applications describes an additive-free, brine-discharge-free solar-thermal desalination method that uses femtosecond laser-etched superwicking black metal to produce fresh water from real ocean water while collecting nearly all remaining salts as solids. Tests using samples from the Pacific, Atlantic, and Indian Oceans show that the self-cleaning surface can prevent salt and mineral build-up, a major limitation of existing solar desalination systems. 31 May – A Phase 3 trial published in the New England Journal of Medicine reports that daraxonrasib, an investigational oral RAS(ON) inhibitor, nearly doubles median overall survival in patients with previously treated metastatic pancreatic cancer, from 6.6 months with standard chemotherapy to 13.2 months.
== Biography == In 1993, he immigrated to Canada. Prior to the formation of DVS Sciences. Dr. Baranov, a senior scientist at MDS SCIEX, was a key member of the research team that developed and promoted the Dynamic Reaction Cell®, which remains today at the pinnacle of quadrupole ICP-MS technology. In 2005, together with Scott D. Tanner and Dmitry Bandura, he began independently developing an ICP-TOF-MS based cytometer and became a researcher at the University of Toronto in March 2005. After securing ample funding by 2010 from various sources, including National Institutes of Health, Ontario Institute for Cancer Research (OICR), the Ministry of Research and Innovation, Ontario Centres of Excellence, Health Technology Exchange, and Genome Canada via the Ontario Genomics Institute, and venture capital from 5 AM Ventures, Vladimir and the DVS Sciences team successfully commercialized their technology, leading to the acquisition of DVS Sciences by Fluidigm in 2014 Baranov was a principal scientist at DVS Sciences (and then Fluidigm) developing instrumental concepts and algorithmics that advance the CyTOF® line of products. He also and played a fundamental role in the development of the MaxPar line of metal-labeling reagents until his retirement in 2019.
(for the number of infected persons). The KdV-SIR equation shares the same form as the Korteweg–De Vries equation in the traveling wave coordinate. An analytical solution to the KdV-SIR equation is written as follows:
Stephen Standfast is designated as his successor. 12 August – Green Party co-leader Chlöe Swarbrick is banned from Parliament for one week after criticising government MPs during a debate on the recognition of Palestine. 15 August: The Supreme Court of New Zealand rules that the Family Court used the wrong legal test to lock up a 20 year old autistic man for 20 years. The Supreme Court rules that riverbeds can be included in Māori customary marine title claims in the eastern Bay of Plenty. KiwiRail agrees to pay HD Hyundai Mipo a settlement of NZ$144 million for the New Zealand Government's 2023 cancellation of the Project iRex ferries. 16 August: Palestinian solidarity protests calling for an end to the Gaza war and sanctions against Israel are held in 20 cities and towns. Staff at Spring Hill Corrections facility quell a riot involving 11 prisoners. About 100 environmental protesters confront Resources Management Minister Shane Jones during his visit to Whangārei. The protesters were opposed to two fast-track projects including the construction of a marina in Waipiro Bay and proposed offshore sand mining in Bream Bay. Multiple trans-Tasman flights are disrupted by a technical fault in Airways New Zealand's main oceanic air control system. 18 August: KiwiRail's Interislander ferry Aratere is retired. Building and Construction Minister Chris Penk announces that the Government will introduce legislation to overhaul the building consent system.
== University of California == Upon graduating B.Sc. from Adelaide in 1905, he accepted the physiologist and cell biologist Jacques Loeb's offer of a (paid) junior position in the Physiology Department of the University of California's School of Medicine; and, according to Hedley Marston, as well as "enjoy[ing] the intellectual companionship and friendship of Jacques Loeb" at Berkeley, he also enjoyed "the pleasant and inspiring association of his colleagues": who included Winthrop J. V. Osterhout, Hardolph Wasteneys, Frederick P. Gay, Wolfgang Ostwald, Carl L. A. Schmidt, and Alonzo E. Taylor. With his developing interest in physical chemistry, and his Bragg-generated interest in mathematics, he produced two papers in 1908 (BR.5, BR.6), offering "[an] extrapolation of ... [his own] mathematical models for cell growth ... to theories to account for the normal rate of growth of individual organisms". While working with Loeb at Berkeley Robertson became interested in the physical chemistry of proteins; and, in 1912, he published a monograph on the subject (BR.9), in German. It was translated into Russian, by V. M. Arkhangeleski of the University of Moscow, in 1913; and an expanded English version of the original monograph was published five years later, in 1918 (BR.32).
Sources: en.wikipedia.org
=== Inflammation === FFAR2 is expressed in various cells involved in the development of inflammatory responses such as neutrophils, monocytes, macrophages, dendritic cells, regulatory T cells, and T helper cells. FFAR2 often appears to be involved in suppressing these cells' pro-inflammatory actions and thereby the development of inflammation. For example: 1) compared to control mice, Ffar2 gene knockout mice developed more severe and unresolving inflammation in colitis, arthritis, peritonitis, and asthma models of inflammation; 2) germ-free mice, which lack intestinal SCFAs, likewise had severer disease in these colitis, arthritis, and asthma models; 3) in a dextran sulphate sodium-induced model of colitis, Ffar2 gene knockout mice developed more severe disease than control mice; 4) two studies found that normal mice but not Ffar2 gene knockout mice fed a prebiotic diet that produces higher intestinal levels of SCFAs were protected from developing allergic responses to food; 5) the latter study also showed that the prebiotic diet was fully protective in Ffar3 gene knockout mice (allergic responses are a subtype of the inflammatory reactions); and 6) studies in mice and humans suggest that FFAR2 is involved in suppressing the pancreatic islet inflammation underlying the development of type 1 diabetes (see previous section). Other studies, however, have reported that FFAR2 promotes inflammation. Two studies found that FFAR2 gene knockdown mice had less severe disease in a dextran sulphate sodium-induce colitis model compared to control mice.
Brincidofovir is one of several experimental drugs administered to a small number of patients to treat Ebola virus disease during the 2014 outbreak. The WHO published a report on the ethics of using unregistered interventions to treat Ebola, where they concluded that "In the particular context of the current Ebola outbreak in West Africa, it is ethically acceptable to offer unproven interventions that have shown promising results in the laboratory and in animal models but have not yet been evaluated for safety and efficacy in humans as potential treatment or prevention."
== Contraindications == Due to its effects on blood pressure (generally a transient increase in systolic blood pressure by 6 mmHg, and diastolic blood pressure by 3 mmHg), bremelanotide is considered contraindicated in people with uncontrolled high blood pressure or cardiovascular disease. As long as bremelanotide is not used more than once in one day, it is not expected to cause more severe increases in blood pressure.
in situ hybridization (ISH) A hybridization probe assay in which a labeled, single-stranded DNA or RNA molecule or nucleic acid analogue containing a sequence that is complementary to a particular DNA or RNA sequence is allowed to hybridize with its complement in situ, i.e. in its natural context, such as within cells or tissue sections (as opposed to within homogeneous samples extracted from cells or tissues, where cellular or histological structure has been lost in the process of obtaining the sample), in order to reveal the precise location of the complementary sequence within this context. The label may be a radioactive compound, fluorescent molecule, or hapten, permitting detection by a variety of visualization techniques. In situ hybridization is commonly used to identify the physical locations of specific DNA sequences such as genes and regulatory elements on chromosomes, which can provide insight into chromosomal structure and integrity; to determine the subcellular locations where various types of RNA accumulate and interact with other molecules; and to visualize the tissues and organs within an organism where specific genes are expressed at various developmental stages (by probing for the genes' RNA transcripts).
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.